Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical is supported by a solid commercial base in rare-disease therapies, with products such as Crysvita, Dojolvi, and Mepsevii providing ongoing revenue while management continues to pursue additional launches and PRV monetization to bridge toward breakeven. The outlook remains constructive because the company still has multiple near-term catalysts in its commercial pipeline, including the upcoming UX111 launch (PDUFA Sep 19), and management has reiterated a plan for FY27 breakeven alongside “significant” expense reductions that could improve operating leverage. Even after the setback in the Phase 3 ASPIRE program, the core investment case is anchored by expected high penetration across a meaningful prevalent pool, but execution will need to offset key risks from reimbursement pressure, competition, and elevated operating expenses that have limited investor confidence.

Ultragenyx Pharmaceutical is viewed negatively because its investment case is increasingly dependent on a narrow set of gene-therapy catalysts that carry high clinical and regulatory risk, while the company has already suffered a major setback with GTX-102 and the removal of an estimated $960M in FY30 revenue and $1.7B in peak sales by FY33 from the model. Although it has four commercial drugs and a broad rare-disease pipeline spanning biologics, small molecules, gene therapy, and nucleic acid products, the business still faces execution risk from delayed enrollment, limited AAV approval history, and heightened post-market scrutiny, even as management shifts focus to expanding Crysvita, Dojolvi, Mepsevii, Genglycos, and ex-US Evkeeza. Financially, the outlook remains weak despite an assumed reduction in OpEx by $1.0B, because FY30 non-GAAP net income is still only $66M, the model depends on first-year profitability in FY30 at $0.63 EPS, and future upside now hinges on uncertain readouts from UX701 in Q4:26 and DTX301 in 1H27 rather than durable, diversified earnings power.